BBLG
Bone Biologics Corp (BBLG)
Healthcare • NASDAQ • $1.32+1.54%
- Symbol
- BBLG
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.32
- Daily Change
- +1.54%
- Market Cap
- $2.36M
- Trailing P/E
- N/A
- Forward P/E
- -0.81
- 52W High
- $6.75
- 52W Low
- $1.05
- Analyst Target
- $22.20
- Dividend Yield
- N/A
- Beta
- 0.53
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics …
Company websiteResearch BBLG on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.